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Abstract: The study was designed to
evaluate IL-6 and TNF-α levels and to
examine their relationship in 27 patients with
hyperthroidism, 23 with hypothyroidism,
and 18 with normal thyroid functions. Mean
serum levels of IL-6 and TNF-α in patients
with untreated hyperthyroidism were higher
than those of control group (p<0.001 for
both). However, these values were lower in
hypothyroidism than in the controls (p<0.01,
p<0.001, respectively). After treatment,
both of the patients groups had IL-6 and
TNF-α values in accordance with those of
controls and these values were decreased in
hyperthyroid patients (p<0.01), but
increased in hypotyhroid ones (p<0.05).
There were significant correlations between
before and after treatment serum IL-6 and
TNF-α values in hyperthyroid patients
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Introduction
Most cytokines are multifunctional. It is also apparent
that certain biologic functions are shared by cytokines
with distinct structural properties, and that many biologic
actions in vivo are the result of synergistic or antagonistic
actions involving two or more cytokines. Cytokines are
likely to play an important role in autoimmune thyroid
disease. These molecules, produced by thyroid follicular
cells, are essential for T and B cell growth and
differentation (1,2).
IL-6 is a 26 kD protein released by fibroblasts, T
lymphocytes, endothelial cells, monocytes (3). It is a
pleiotropic cytokine exerting multiple biologic activities on
different types of target cells including induction of B cell
differentiation (4), stimulation of myeloma, hybridoma
and plasmacytoma growth (5), activation of T cellsthymocytes (6), induction of acute phase proteins (7),
stimulation of hemopoietic precursor cell growth and
differentiation (8), induction of myelomonocytic

(r=0.787, r=0.692, respectively) and
between before and after treatment serum
IL-6 and TNF-α in hypothyroid patients
(r=0.723, r=0.552, respectively). There
were significant correlations between serum
IL-6 and TNF-α in control subjects
(r=0.425).
We concluded that serum IL-6 and TNF-α are
increased in patients with hyperthyroidism,
but

decreased

in

patients

with

hypothyroidism subjects, and become normal
by successful surgical treatment or ten or
more months after medical treatment.
Key
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differentiation (9), pyrogenic action (10), inhibition of cell
growth (11) and induction of ACTH synthesis (12).
TNF-α is a multifunctional cytokine produced by
macrophages and other cells during inflamatory
responses (13). TNF-α can induction of acute phase
proteins by hepatocytes and induction of cytocine
production by T cells (14). In the present study, we
report that serum levels of the cytokines IL-6 and TNF-α
are increased in patients with hyperthyroidism and
decreased in patients with hypothyroidism.
Material and Methods
Twenty seven hyperthyroid, 23 hypothyroid patients,
and 18 normal subjects were studied. The ages
(mean±SD) of the hyperthyroid and hypothyroid patients
and normal subjects were 63±3, 55±2, and 58±4 yr,
respectively. The male to female rations of the
hyperthyroid and hypothyroid and control groups were
14:13, 10:13, 9:9, respectively. Sixteen hypothyroid and

25

Serum IL-6 and TNF-α in Patients With Thyroid Disorders

Hyperthyroid

Hypothyroid

Control

Before

After

Before

After

T4 (µg/dl)

15.5±6.1

4.8±1.9

2.9±0.9

4.1±1.6

4.4±1.7

T3 (ng/dl)

227.9±69.5

117.2±22.3

44±8.5

105.2±16.3

110.1±18.6

TSH (µU/ml)

2.3±0.8

5±0.9

38.2±10.4

6.1±2.3

5.5±1.2

IL-6 (pg/ml)

14.5±4.4*

11.1±2.3•

8.2±2.4**

9.9±3.2#

18.3±5.5*

•

TNF-α(pg/ml)

14.3±1.7

11.4±2.4*

Table 1.

Biochemical parameters of thyroid
disease and normal subjects.

10.6±2.2

#

13.2±3.2

13.8±1.6

30

30

20

20
IL-6 (pg/ml)

IL-6 (pg/ml)

*p<0.001, ** p<0.01 vs. control subjects. • p<0.01, # p<0.05 vs. before treatment.
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Figure 1.

Linear regression analysis of the relationship between
serum IL-6 and TNF-α in hyperthyroid patients before
treatment. The regression equation y=2.27+0.669x;
r=0.787; p<0.001.

22 hyperthyroid patients (10 thyroid adenomectomy)
were restudied when they were euthyroid after surgical
treatment and 10 or more months of treatment. All of
control subject and patient groups were not taking any
medication known to affect thyroid metabolism.
Blood was drawn after an overnight fast, centrifuged,
and serum aliquots were stored at -80˚C until
determination. Serum T4, T3, TSH levels were determined
by automated chemiluminescence assay (Ciba Corning
Diagnostics Corp. Medfield, MA 02052 USA). Serum IL-6
and TNF-α were measured by an enzyme-linked
immunosorbent assay (Quantikine™, Human TNF-α
immunoassay, CN DTA 50; Quantikine™, Human IL-6
immunoassay, CN D 6050).
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Figure 2.

Linear regression analysis of the relationship between
serum IL-6 and TNF-α in hyperthyroid patients after
treatment. The regression equation y=5.33+0.412x;
r=0.692; p<0.001.

Statistical analysis
The results were expressed as means ± SD. Statistical
analysis was performed by Student’s paired t-test. Linear
regression analysis was used for comparison of IL-6 and
TNF-α levels in thyroid disease subjects. Differences
were considered significant if the P value was less than
0.05.
Results
Significant increased IL-6 and TNF-α levels in
untreated hyperthyroid patients were found when
compared with the healthy controls (p<0.001, for both).
On the contrary, relatively decreased IL-6 and TNF-α
levels in untreated hypothyroid patients were observed
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Figure 3.

Linear regression analysis of the relationship between
serum IL-6 and TNF-α in hypothyroid patients before
treatment. The regression equation y=1+0.63x; r=0.723;
p<0.001.

(p<0.01, p<0.001, respectively). After treatment, serum
IL-6 and TNF-α values were decreased in hyperthyroid
patients (p<0.01), but increased in hypothyroid patients
(p<0.05). On the other hand, serum IL-6 and TNF-α
levels in hyperthyroid patients were significantly
decreased after treatment (p<0.01), but increased
(p<0.05) in hypothyroid patients when compared to the
pretreatment values. Positive correlations between
before and after treatment serum IL-6 and TNF-α levels
were found in hyperthyroidism (r=0.787, r=0.692, Fig
1-2, respectively) and hypothyroidism (r=0.723,
r=0.552, Fig 3-4, respectively). Additionally, a positive
correlation between serum IL-6 and TNF-α levels was
also found in control subjects (r=0.425). However,
neither IL-6 nor TNF-α demonstrated correlation with T3,
T4 and TSH levels. After treatment, IL-6, TNF-α, T3, T4,
TSH levels of hypertyhroid and hypothyroid patients did
not differ statistically from control subjects (p>0.05;
Table 1).
Discussion
Many in vivo models demonstrated the role of
cytokines in pathophysiology have demonstrated that a
given inflammatory stimulus results not in the generation
of a single cytokine, but rather a complex cascade of
cytokine release (15,16). In accordance with this, our
demonstration of circulating TNF following thyroid
disorders has led us to examine the production of other
cytokines, in particular IL-6. We chose to study IL-6
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Figure 4.

Linear regression analysis of the relationship between
serum IL-6 and TNF-α in hypothyroid patients after
treatment. The regression equation y=5.2+0.35x;
r=0.552; p<0.01.

because TNF-α has been demonstrated to be an
important stimulus for IL-6 production (17)
We have shown that IL-6 and TNF-α levels are
increased in the circulation in untreated hyperthyroid
patients and decreased in untreated hypothyroid patients.
TNF-α is polypeptide with multitudes of effects. It plays
a major role in the immunological cascade leading to
inflammatory response, and stimulating the release of a
variety of other mediators, including IL-2, IL-6, and
platelet activating factor (18,19). TNF-α is a
macrophage/monocyte-derived cytokine that has been
proposed as an early proximal mediator of many of the
metabolic and physiologic responses. TNF-α is believed to
play a central role in the development of sepsis (20) and
ischemic colitis (21). IL-6 stimulates the hepatic synthesis
of proteins (22,23), favors terminal differantiation of B
cells into Ig-secreting cells, enhances the proliferation of
multipotential hematopoietic progenitors and plays a role
in the growth and differantiation of several cell types
(22,24). In hyperthyroidism, increased serum IL-6 could
originate from several sources including the thyroid
gland, blood mononuclear cells, and bone tissue. In
Graves disease (GD), although follicle cells are able to
express certain cytokines, intrathyroidal lymphocytes are
the main source of IL-6 production (25). Weetmann et al
(26) were unable to observe any significant difference in
serum IL-6 concentrations between normal subjects and
hyperthyroid GD patients. Bartalena et al (27) found
increased serum IL-6 concentrations in GD patients. Our
finding of an increase in serum levels of IL-6, similar to
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that reported in graves disease (25), again suggests that
a similar effector immunological mechanism might be
involved in our patients as in GD. Thus, increased
intrathyroidal production of IL-6 in hyperthyroid patients
is one source of elevated IL-6 levels in serum. However,
because TNF-α stimulates IL-6 production by osteoblasts
(28,29), elevated levels of this cytokine may contribute to
the increased production of IL-6. In hypothyroidism,
Because decreased intrathyroidal production of IL-6 and
decreased TNF-α levels, serum IL-6 concentration might
be decreased. Our results provide support for the notion

of a cascade effect of these cytokines by demonstrating a
positive correlation between IL-6 and TNF-α. After
treatment, serum IL-6 and TNF-α concentrations were
decreased in hyperthyroid patients, and increased in
hypothyroid patients.
In conclusion, the present results show that IL-6 and
TNF-α levels are considerably elevated in patients with
hyperthyroid, decreased in patients with hypothyroid and
normalized by succesful surgical treatment or treatment
of medicine. Further in vivo and in vitro experiments will
be required to confirm these findings.
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